FDA — authorised 12 November 1985
- Application: ANDA070225
- Marketing authorisation holder: LUITPOLD
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 VERAPAMIL HYDROCHLORIDE in United States
FDA authorised VERAPAMIL HYDROCHLORIDE on 12 November 1985
Marketing authorisations
FDA — authorised 12 November 1985
- Application: ANDA070617
- Marketing authorisation holder: LUITPOLD
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 16 December 1985
- Application: ANDA070451
- Marketing authorisation holder: INTL MEDICATION
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 20 August 1986
- Application: ANDA070341
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 August 1986
- Application: ANDA070340
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1986
- Application: ANDA070468
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1986
- Application: ANDA070855
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1986
- Application: ANDA070856
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1986
- Application: ANDA070482
- Marketing authorisation holder: MUTUAL PHARM
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1986
- Application: ANDA070483
- Marketing authorisation holder: MUTUAL PHARM
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1986
- Application: ANDA071019
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 October 1986
- Application: ANDA071366
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 October 1986
- Application: ANDA070994
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 October 1986
- Application: ANDA070995
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 October 1986
- Application: ANDA071367
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 December 1986
- Application: NDA019152
- Marketing authorisation holder: PFIZER
- Local brand name: CALAN SR
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 6 May 1987
- Application: ANDA070738
- Marketing authorisation holder: HOSPIRA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 6 May 1987
- Application: ANDA070739
- Marketing authorisation holder: HOSPIRA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 6 May 1987
- Application: ANDA070740
- Marketing authorisation holder: HOSPIRA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 6 May 1987
- Application: ANDA070737
- Marketing authorisation holder: HOSPIRA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 13 January 1988
- Application: ANDA071489
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 5 April 1988
- Application: ANDA071881
- Marketing authorisation holder: HERITAGE
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 25 May 1988
- Application: ANDA071423
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 25 May 1988
- Application: ANDA071424
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 January 1989
- Application: ANDA072124
- Marketing authorisation holder: PLIVA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 January 1989
- Application: ANDA072125
- Marketing authorisation holder: PLIVA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 February 1989
- Application: ANDA071483
- Marketing authorisation holder: RISING
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 May 1990
- Application: NDA019614
- Marketing authorisation holder: AZURITY
- Local brand name: VERELAN
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 31 July 1992
- Application: ANDA073568
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 26 February 1993
- Application: ANDA072233
- Marketing authorisation holder: MARSAM PHARMS LLC
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 29 June 1993
- Application: ANDA072923
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 June 1993
- Application: ANDA072924
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 September 1993
- Application: ANDA073485
- Marketing authorisation holder: MARSAM PHARMS LLC
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 31 January 1994
- Application: ANDA074330
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 28 July 1995
- Application: ANDA072888
- Marketing authorisation holder: BEDFORD
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 February 1996
- Application: ANDA072751
- Marketing authorisation holder: PLIVA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 February 1996
- Application: NDA020552
- Marketing authorisation holder: PFIZER
- Local brand name: COVERA-HS
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 1 March 1996
- Application: ANDA072922
- Marketing authorisation holder: PLIVA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 23 March 1996
- Application: ANDA074587
- Marketing authorisation holder: RISING
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 25 May 1999
- Application: ANDA075072
- Marketing authorisation holder: STRIDES PHARMA INTL
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 9 August 2007
- Application: ANDA078306
- Marketing authorisation holder: RISING
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 17 September 2009
- Application: ANDA078906
- Marketing authorisation holder: GLENMARK PHARMS LTD
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 3 August 2011
- Application: ANDA090700
- Marketing authorisation holder: GLENMARK PHARMS LTD
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 30 December 2011
- Application: ANDA090529
- Marketing authorisation holder: SUN PHARM INDS INC
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 20 April 2012
- Application: ANDA200878
- Marketing authorisation holder: APOTEX CORP
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 18 June 2018
- Application: ANDA211035
- Marketing authorisation holder: SOMERSET
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 18 June 2018
- Application: ANDA211015
- Marketing authorisation holder: SOMERSET THERAPS LLC
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 13 July 2018
- Application: ANDA210994
- Marketing authorisation holder: AMNEAL
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 28 December 2018
- Application: ANDA211370
- Marketing authorisation holder: MICRO LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 17 March 2020
- Application: ANDA213352
- Marketing authorisation holder: NEPHRON
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 25 March 2020
- Application: ANDA213232
- Marketing authorisation holder: CAPLIN
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA — authorised 6 July 2020
- Application: ANDA212965
- Marketing authorisation holder: EUGIA PHARMA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 15 October 2020
- Application: ANDA214215
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 15 October 2020
- Application: ANDA214361
- Marketing authorisation holder: GLAND
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 March 2022
- Application: ANDA215829
- Marketing authorisation holder: HERITAGE
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 April 2024
- Application: ANDA216471
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 13 November 2025
- Application: ANDA218218
- Marketing authorisation holder: ASPIRO
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 24 November 2025
- Application: ANDA219252
- Marketing authorisation holder: ZYDUS LIFESCIENCES
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA
- Application: ANDA070696
- Marketing authorisation holder: SMITH AND NEPHEW
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070697
- Marketing authorisation holder: SMITH AND NEPHEW
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
FDA
- Application: ANDA072799
- Marketing authorisation holder: WATSON LABS
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070348
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070672
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: VERAPAMIL HCL
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA070695
- Marketing authorisation holder: SOLOPAK
- Local brand name: VERAPAMIL HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
VERAPAMIL HYDROCHLORIDE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is VERAPAMIL HYDROCHLORIDE approved in United States?
Yes. FDA authorised it on 12 November 1985; FDA authorised it on 12 November 1985; FDA authorised it on 16 December 1985.
Who is the marketing authorisation holder for VERAPAMIL HYDROCHLORIDE in United States?
LUITPOLD holds the US marketing authorisation.